Cardiol Therapeutics annual book value per share
2020
2021
2022
2023
2024
2025
Cardiol Therapeutics Book Value Per Share Growth & History (CRDL)
Cardiol Therapeutics's book value per share was CA$0.18 for fiscal 2025.
View full Cardiol Therapeutics company overviewCardiol Therapeutics annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | CA$0.18 | -CA$0.12 | −40.43% |
| 2024 | 2024-12-31 | CA$0.30 | -CA$0.13 | −30.74% |
| 2023 | 2023-12-31 | CA$0.43 | -CA$0.38 | −46.97% |
| 2022 | 2022-12-31 | CA$0.82 | -CA$0.42 | −33.79% |
| 2021 | 2021-12-31 | CA$1.23 | CA$0.79 | +177.00% |
| 2020 | 2020-12-31 | CA$0.44 | — | — |
Cardiol Therapeutics quarterly book value per share
Q4.21
Q4.22
Q4.23
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | CA$0.21 | CA$0.07 | +45.95% |
| Q1 2026 | 2026-03-31 | CA$0.22 | CA$0.00 | +1.62% |
| Q4 2025 | 2025-12-31 | CA$0.18 | -CA$0.12 | −40.43% |
| Q3 2025 | 2025-09-30 | CA$0.11 | — | — |
| Q2 2025 | 2025-06-30 | CA$0.14 | — | — |
| Q1 2025 | 2025-03-31 | CA$0.21 | — | — |
| Q4 2024 | 2024-12-31 | CA$0.30 | -CA$0.13 | −30.74% |
| Q4 2023 | 2023-12-31 | CA$0.43 | -CA$0.38 | −46.97% |
| Q4 2022 | 2022-12-31 | CA$0.82 | -CA$0.42 | −33.79% |
| Q4 2021 | 2021-12-31 | CA$1.23 | — | — |
Cardiol Therapeutics book value per share trends
Over the last five fiscal years, Cardiol Therapeutics's book value per share decreased from CA$0.44 to CA$0.18, a change of -CA$0.27. The latest reported quarter, Q2 2026, shows CA$0.21.
About the metric
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
Calculation and source
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cardiol Therapeutics source filings ↗